Welcome Center  |   Log In  |   Register  |   Follow Us  Facebook  Twitter Google Plus

From VerusMed Neurology

Rituximab reduces inflammatory brain lesions and clinical relapses in MS patients

A new study indicates that a single course of rituximab reduces inflammatory brain lesions and clinical relapses for as long as 48 weeks in patients with relapsing-remitting multiple sclerosis.

From our partners at VerusMed
verusmed.com

Sponsored by The Doctor’s Channel